Loading
A phase 1/2 trial of Fulvestrant, Abemaciclib in ovarian cancer and metastatic cancer, run by Incyclix Bio, now recruiting.
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer is a phase 1/2 interventional study registered as NCT05735080 by Incyclix Bio, with 150 participants planned, started 2023-03-28 and due to reach its primary completion in 2027-07. Interventions recorded: INX-315, Fulvestrant, Abemaciclib. Conditions listed: Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Abemaciclib, Fulvestrant, Metastatic cancer (cancer that has spread).
Shares Fulvestrant, Metastatic cancer (cancer that has spread).
Shares Abemaciclib, Metastatic cancer (cancer that has spread).
Shares Fulvestrant, Metastatic cancer (cancer that has spread).
Shares Abemaciclib, Fulvestrant, Metastatic cancer (cancer that has spread).
Shares Fulvestrant, Metastatic cancer (cancer that has spread).
Shares Fulvestrant, Metastatic cancer (cancer that has spread).
Shares Fulvestrant, Metastatic cancer (cancer that has spread).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/